SZM679

SZM679 is a potent, orally active, and highly selective small molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1). It exhibits strong antinecroptotic activity with a Kd of 8.6 nM for RIPK1 and over 5000 nM for RIPK3, indicating high specificity. Preclinical studies demonstrate that SZM679 can reverse tumor necrosis factor-induced systemic inflammatory response syndrome and ameliorate learning and memory dysfunction in Alzheimer's disease models by reducing Tau hyperphosphorylation, neuroinflammation, neuronal loss, and RIPK1 phosphorylation in the brain. These findings suggest its potential as a novel therapeutic agent targeting necroptosis pathways in neurodegenerative diseases such as Alzheimer's disease[2][3][4][5][7].